Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 831

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 831
---
’s investments in corporate bonds were due to changes in interest rates and non-credit related factors. The credit ratings of these investments in the Company’s portfolio have not been downgraded below investment grade status. The contractual terms of these investments do not permit the issuer to repay principal at a price less than the amortized cost bases of the investments, which is equivalent to the par value on the maturity date. The Company expects to

F-56

TABLE OF CONTENTS

CARA THERAPEUTICS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data) recover the entire amortized cost bases of these securities on the maturity date. The Company does not intend to sell these investments, and it is not “more likely than not” that the Company will be required to sell these investments, before recovery of their amortized cost bases. The Company held 1 out of 2 positions for its corporate bonds, that were in unrealized loss positions as of December 31, 2023. The Company classifies its marketable debt securities based on their contractual maturity dates. As of December 31, 2023, the Company’s marketable debt securities mature at various dates through November 2024. The amortized cost and fair values of marketable debt securities by contractual maturity were as follows:

| ​                     | ​ | ​ | As of December 31, 2023 |   |        |   |   |   |            |   |        |   | ​ | ​ | As of December 31, 2022 |   |        |   |   |   |            |   |        |   | ​ |
|:----------------------|:--|:--|:------------------------|:--|-------:|:--|:--|:--|:-----------|:--|-------:|:--|:--|:--|:------------------------|:--|-------:|:--|:--|:--|:-----------|:--|-------:|:--|:--|
| Contractual maturity  | ​ | ​ | Amortized Cost          |   |        |   | ​ | ​ | Fair Value |   |        |   | ​ | ​ | Amortized Cost          |   |        |   | ​ | ​ | Fair Value |   |        |   | ​ |
| Less than one year    | ​ | ​ | ​                       | $ | 49